Partners in Care: How Modern Medicine Is Closing the Gap on Men’s Health
Every June, the United States observes Men’s Health Month, an awareness campaign first formalized in 1994 when Congress passed legislation establishing National Men’s Health Week. Signed into law by President Bill Clinton, the observance was set for the week leading up to Father’s Day and has since expanded into a month-long campaign coordinated by the Men’s Health Network, which sets a new theme each year.
The 2026 theme is “Partners in Care: For Better Lifespans Across the Lifespan,” recognizing that men’s health outcomes improve when patients are supported by spouses, family members, friends, and clinicians who help them seek care, follow through on treatment, and stay engaged across decades of life. The data underlying the theme is sobering. Men in the United States die on average roughly six years earlier than women, are diagnosed with cardiovascular disease at higher rates, face higher mortality from several major cancers including colorectal and prostate, and are statistically less likely to seek mental health support. The companies in this article are working on those exact problems.
A Sector Increasingly Built Around Specialized Care
Beyond awareness, the structure of healthcare delivery for men is also shifting. Direct-to-consumer telehealth platforms are reaching patients who historically avoided primary care, and the FDA continues to grant expedited designations, including Breakthrough Therapy and Fast Track, to programs in psychiatry, cardiology, and oncology. Both trends are creating measurable progress in conditions that disproportionately affect men.
The companies that follow are positioned across the three categories most central to the men’s health conversation: mental health, cardiovascular disease, and oncology. Each is at a different stage of clinical or commercial development, and each is approaching meaningful catalysts in the second half of 2026.
Mental Health: Reaching Patients Who Have Historically Avoided Care
Men remain significantly less likely than women to be diagnosed with or treated for depression and anxiety, even as suicide rates among American men run nearly four times higher. The two companies below address that gap from opposite ends — one through next-generation psychiatric therapeutics, the other through scaled direct-to-consumer access.
- Definium Therapeutics (DFTX): Late-stage clinical biopharmaceutical company developing therapeutics for psychiatric and neurological disorders. Its lead candidate, DT120 ODT, holds FDA Breakthrough Therapy Designation for generalized anxiety disorder. On June 22, 2026, Definium reported positive Phase 3 Emerge topline results in major depressive disorder, with DT120 ODT meeting the primary endpoint and demonstrating an LS mean change in MADRS total score of -13.3 versus -5.2 for placebo (p<0.0001). Two additional Phase 3 GAD (Generalized Anxiety Disorder) readouts and Phase 2a DT402 data in autism spectrum disorder are expected later in 2026, supported by $373.4 million in cash at March 31, 2026 and a subsequently priced $700 million upsized public offering.
- Hims & Hers Health (HIMS): Direct-to-consumer health and wellness platform serving more than 2.6 million subscribers across mental health, sexual health, dermatology, weight loss, and testosterone support. The company reported $2.35 billion in 2025 revenue, up 59% year-over-year, and $608.1 million in Q1 2026 revenue, with full-year 2026 guidance raised to $2.8 to $3.0 billion. On June 2, 2026, Hims & Hers completed its acquisition of Eucalyptus, extending its presence across Australia, Canada, Germany, Japan, and the United Kingdom.
Cardiovascular Care: The Single Largest Driver of Male Mortality
Heart disease remains the leading cause of death for American men, accounting for roughly one in four male deaths in the United States. Two companies in this brief are advancing pivotal-stage technology aimed at the inflammatory and electrical pathologies that drive that mortality.
- Cardiol Therapeutics (CRDL): Late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx, targets the inflammasome pathway implicated in pericarditis, myocarditis, and heart failure. The pivotal Phase III MAVERIC trial in recurrent pericarditis surpassed 75% enrollment in late April 2026, with target recruitment expected by the end of Q2 2026. The completed Phase II ARCHER study in acute myocarditis was published in ESC Heart Failure, and the Phase II MAvERIC-Pilot results were accepted for publication in the Journal of the American Heart Association in May 2026. A second program, CRD-38, is advancing toward an IND filing, and the company reported a cash runway into Q4 2027.
- Pulse Biosciences (PLSE): Bioelectric medicine company developing its proprietary Nanosecond Pulsed Field Ablation (nsPFA) energy through the nPulse platform. The lead program, the nPulse Cardiac Catheter System, is being developed for atrial fibrillation. The U.S. IDE pivotal trial, NANOPULSE-AF, began enrolling patients in early April 2026, with enrollment completion anticipated in early Q4 2026. At Heart Rhythm 2026, the company presented one-year European feasibility data showing 100% procedural success at six months (95 of 95 evaluable patients), 96% at twelve months (51 of 53), and a 90% Kaplan-Meier estimate of freedom from atrial arrhythmias at twelve months. Pulse ended Q1 2026 with $68.3 million in cash.
Oncology: Precision Delivery in Cancers That Disproportionately Affect Men
Colorectal cancer is the third most commonly diagnosed cancer in American men and the second leading cause of cancer death. The precision oncology landscape is moving toward conditionally activated therapeutics designed to deliver toxic payloads selectively within tumor tissue, sparing the healthy tissue around it.
- CytomX Therapeutics (CTMX): Clinical-stage oncology biopharmaceutical company developing conditionally activated, masked PROBODY therapeutics that remain inert in systemic circulation and activate within the tumor microenvironment. Its lead asset, varsetatug masetecan (Varseta-M, CX-2051), is the only EpCAM-targeted antibody-drug conjugate in clinical development and is being evaluated in a Phase 1 dose optimization study in advanced colorectal cancer. Data presented in March 2026 showed confirmed response rates of 32% at the 10 mg/kg Q3W dose and 20% at the 8.6 mg/kg dose, with estimated progression-free survival of 7.1 and 6.8 months, respectively. On June 3, 2026, CytomX announced an expansion of its Regeneron collaboration carrying a $37 million target selection payment and up to approximately $4 billion in total potential milestones to develop conditionally activated bispecific cancer therapies.
Across the Lifespan
The 2026 theme of Men’s Health Month treats the patient and the support network as inseparable. The companies above operate on the same logic. Definium Therapeutics ($DFTX) and Hims & Hers ($HIMS) are working to make mental health support more accessible to men who have historically avoided it. Cardiol Therapeutics ($CRDL) and Pulse Biosciences ($PLSE) are advancing late-stage cardiovascular programs addressing the single largest driver of male mortality. And CytomX Therapeutics ($CTMX) is developing a first-in-class delivery platform for one of the cancers that affects men most severely.
Men’s Health Month exists to push back on the patterns that have historically shaped male health outcomes: delayed diagnoses, avoided conversations, and undertreated conditions. In 2026, the institutional and clinical infrastructure built around the observance reflects how far the field has moved. ‘Better lifespans, across the lifespan’ is no longer aspirational. It is being engineered, clinical milestone by clinical milestone, by the companies treating the conditions that have most often cut men’s lives short.
This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. PRISM MarketView is not a registered investment advisor. Companies mentioned are constituents of PRISM indexes; inclusion in an index does not imply endorsement. Information is sourced from public filings and reports believed to be reliable but is not guaranteed to be accurate or complete. Readers should conduct their own research and consult a qualified financial advisor before making investment decisions. Past performance is not indicative of future results.
